OKUR
OnKure Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.95
−0.34%Next report
Analyst consensus
- Next report date
- Nov 5, 2026
- EPS estimate
- -$0.36
- Revenue estimate
- $166.7K
Latest reported
- Last report date
- Aug 4, 2026
- EPS actual
- -$0.31
- EPS estimate
- -$0.54
- Revenue actual
- —
- Revenue estimate
- $166.7K
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 6
- EPS misses (12Q)
- 4
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +102.3%
- Revenue beats (12Q)
- —
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $18
- PT range
- $14 – $21
- Analysts
- 2
2 Buy0 Hold0 Sell
No earnings call summaries available
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 4, 2026 | -$0.54 | -$0.31 | Beat 42.06% | — |
| May 5, 2026 | -$0.81 | -$1.11 | Miss -37.04% | — |
| Mar 9, 2026 | -$1.15 | $3.40 | Beat 395.14% | — |
| Nov 6, 2025 | -$1.20 | -$1.09 | Beat 9.17% | — |
| Aug 12, 2025 | -$1.23 | -$1.14 | Beat 7.32% | — |
| Mar 10, 2025 | -$0.86 | -$1.37 | Miss -59.30% | — |
| Nov 7, 2024 | -$0.97 | -$1.10 | Miss -13.40% | — |
| Dec 31, 2023 | -$5.78 | -$7.00 | Miss -21.11% | — |
| Sep 30, 2023 | -$5.71 | -$1.44 | Beat 74.82% | — |
| Jun 30, 2023 | -$5.30 | -$0.61 | Beat 88.43% | — |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 5, 2026